Document Detail

Pharmacology and clinical experience with simvastatin.
MedLine Citation:
PMID:  11336576     Owner:  NLM     Status:  MEDLINE    
Simvastatin (Zocortrade mark, Merck) is a safe and effective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin potently lowers total and low density lipoprotein (LDL) cholesterol. Simvastatin was the first cholesterol-lowering agent that reduced total mortality in a randomised clinical trial. Simvastatin is effective at reducing total mortality, myocardial infarction, coronary mortality and the incidence of stroke or transient ischemic attack in patients with coronary heart disease and hypercholesterolemia. Simvastatin, like other statins, also has non-lipid mechanisms of action. These include anti-inflammatory effects, antiproliferative effects on smooth muscle cells and an upregulation of endothelial nitric oxide synthase. Overall, simvastatin has an excellent safety profile. Simvastatin, along with other statins, has made a significant impact on the morbidity and mortality from coronary heart disease.
D C Hess; S C Fagan
Related Documents :
10468086 - Future cardiovascular end point studies: where will the research take us?
11416416 - Hypercholesterolemia in the elderly: evaluation and treatment.
20886236 - Genetic variants in the kif6 region and coronary event reduction from statin therapy.
15809366 - White blood cell count predicts reduction in coronary heart disease mortality with prav...
16684026 - Results of the multicenter renewal 3 avt clinical study of cardiac resynchronization de...
16492306 - Altered autonomic cardiac control predicts restenosis after percutaneous coronary inter...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  2     ISSN:  1465-6566     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-05-04     Completed Date:  2002-10-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  153-63     Citation Subset:  IM    
Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arteriosclerosis / drug therapy,  etiology
Cholesterol, LDL / blood
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Coronary Disease / prevention & control
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  pharmacology*,  therapeutic use*
Hypercholesterolemia / blood,  complications,  drug therapy*
Simvastatin / adverse effects,  pharmacology*,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
Next Document:  Amlodipine/benazepril: fixed dose combination therapy for hypertension.